Used primarily in pharmaceutical research, this compound functions as a cereblon E3 ligase modulator. It plays a key role in targeted protein degradation, particularly in the development of PROTACs (proteolysis-targeting chimeras). By binding to cereblon, it facilitates the ubiquitination and subsequent degradation of specific disease-related proteins. Its structure enables conjugation with other targeting ligands, making it valuable in oncology and immunomodulatory drug design. It is especially explored for its potential in treating hematological cancers and resistant tumor types.